Creative Medical Technology Holdings Inc (CELZ)

$3.31

-0.19

(-5.43%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $3.28
    $3.49
    $3.31
    downward going graph

    0.91%

    Downside

    Day's Volatility :6.0%

    Upside

    5.14%

    downward going graph
  • $2.90
    $10.28
    $3.31
    downward going graph

    12.38%

    Downside

    52 Weeks Volatility :71.79%

    Upside

    67.81%

    downward going graph

Returns

PeriodCreative Medical Technology Holdings IncIndex (Russel 2000)
3 Months
-24.52%
0.0%
6 Months
-47.46%
0.0%
1 Year
-28.97%
0.0%
3 Years
-85.02%
-22.3%

Highlights

Market Capitalization
4.7M
Book Value
$5.69
Earnings Per Share (EPS)
-4.07
Wall Street Target Price
30.0
Profit Margin
0.0%
Operating Margin TTM
-20316.32%
Return On Assets TTM
-34.27%
Return On Equity TTM
-53.71%
Revenue TTM
17.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-83.89999999999999%
Gross Profit TTM
39.8K
EBITDA
-6.0M
Diluted Eps TTM
-4.07
Quarterly Earnings Growth YOY
3.59
EPS Estimate Current Year
-3.29
EPS Estimate Next Year
-2.58
EPS Estimate Current Quarter
-0.84
EPS Estimate Next Quarter
-0.85

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Creative Medical Technology Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 806.34%

Current $3.31
Target $30.00

Technicals Summary

Sell

Neutral

Buy

Creative Medical Technology Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings Inc
9.6%
-47.46%
-28.97%
-85.02%
-85.02%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
67.81%
22.72%
33.57%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings Inc
NA
NA
NA
-3.29
-0.54
-0.34
NA
5.69
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
45.91
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings Inc
Buy
$4.7M
-85.02%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$596.5B
417.73%
45.91
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Creative Medical Technology Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.0K → 8.0K (in $), with an average increase of 62.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.04M → -1.55M (in $), with an average decrease of 49.6% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 66.1%

Institutional Holdings

  • Aaron Wealth Advisors LLC

    1.46%

  • Vanguard Group Inc

    1.32%

  • Virtu Financial LLC

    1.22%

  • Two Sigma Advisers, LLC

    1.12%

  • Two Sigma Investments LLC

    1.11%

  • HRT FINANCIAL LLC

    0.99%

Company Information

creative medical technology holdings, inc., through its subsidiaries, engages in the stem cell research and developing applications to treat male sexual dysfunction and related issues. the company markets its erectile dysfunction (ed) treatment under the caverstem name to physicians for use with their patients suffering from ed. creative medical technology holdings, inc. was incorporated in 1998 and is based in phoenix, arizona. creative medical technology holdings, inc. is a subsidiary of creative medical health, inc.

Organization
Creative Medical Technology Holdings Inc
Employees
4
CEO
Mr. Timothy Warbington
Industry
Miscellaneous

Discover More

FAQs